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intestinal, and respiratory tracts, as 
well as wounds; bloodstream infec-
tion is associated with higher death 
rates than infection at other sites (4). 
Hand carriage is probably the biggest 
factor in transmission of extended-
spectrum β-lactamase producers, and 
there is little evidence to suggest that 
carriers of carbapenemase-producing 
K.  pneumoniae would be different. 
Environmental contamination plays 
a limited role in transmission of the 
organism (3). Caregivers should be 
aware that multidrug-resistant or-
ganisms of nosocomial origin can 
be transmitted in the community (5). 
Acquisition of such strains is prob-
ably of negligible importance in an 
otherwise healthy person. However, 
consequences may be different if the 
recipient of the strain is a debilitated 
patient.
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Alternatives to 
Ciproﬂ  oxacin Use 
for Enteric Fever, 
United Kingdom  
To the Editor: In cases of ty-
phoid and paratyphoid fever, it is of-
ten necessary to commence treatment 
before the results of laboratory sensi-
tivity tests are available. It is therefore 
important to be aware of optional drug 
therapies available because some or-
ganisms may be resistant to key anti-
microbial drugs. For typhoid and para-
typhoid, ciproﬂ   oxacin has become 
the ﬁ  rst-line drug of choice since the 
widespread emergence and spread of 
strains resistant to chloramphenicol, 
ampicillin, and trimethoprim (1).
The Laboratory of Enteric Patho-
gens (LEP) of the Health Protection 
Agency of England and Wales is the 
reference center for Salmonella enter-
ica serovars Typhi and Paratyphi A for 
the United Kingdom; as such, this lab-
oratory receives isolates from all cases 
of infection. Isolates are screened by 
breakpoint  for resistance to antimi-
crobial drugs at the following levels: 
chloramphenicol, 8 mg/L; ampicillin, 
8 mg/L; trimethoprim, 2 mg/L; cipro-
ﬂ  oxacin, 0.125 mg/L (decreased sus-
ceptibility); and 1.0 mg/L (high-level 
resistance), ceftriaxone, 1 mg/L, and 
cefotaxime, 1 mg/L. The levels for 
testing for resistance to chlorampheni-
col, ampicillin, trimethoprim, ceftri-
axone, and cefotaxime correspond to 
internationally accepted therapeutic 
levels for these antimicrobial agents. 
In contrast, the levels for ciproﬂ  oxa-
cin (0.125 and 1.0 mg/L) have been 
chosen after observations of treatment 
failures at levels when used at below 
the expected recommended serum 
concentrations (2,3). Since 2005, a 
proportion of isolates exhibiting de-
creased susceptibility and high-level 
resistance to ciproﬂ  oxacin have been 
tested for resistance to azithromycin 
by Etest (AB Biodisk, Solna, Swe-
den), using drug-sensitive strains of S. 
Typhi and S. Paratyphi A as controls. 
From January 2001 through De-
cember 2006, LEP reported 1,215 
cases of S. Typhi infection and 1,274 
cases of S. Paratyphi A infection. Of 
these,  ≈60% (1,493) reported recent 
travel abroad; India and Pakistan were 
the most frequently visited countries 
(4). Other cases were associated with 
persons who had a history of such trav-
el, but the numbers involved were dif-
ﬁ  cult to document accurately because 
of underreporting of foreign travel and 
other communication problems. 
For  S.  Typhi, the occurrence of 
isolates resistant to ciproﬂ  oxacin  at 
0.125 mg/L increased from 60 (35%) 
of 170 in 2001 to 169 (70%) of 240 
cases in 2006, with 4.8 (2%) of isolates 
in 2006 resistant at 1.0 mg/L (Table). 
The corresponding ﬁ  gures for S. Para-
typhi A were 58 (25%) of 232 cases 
in 2001, rising to 84% in 2004, with 
an incidence of 73% in 2006; 9% of 
these were resistant to ciproﬂ  oxacin at 
1.0 mg/L (Table). Moreover, in 2006, 
56 isolates of S. Typhi (23% of total) 
exhibited resistance to chlorampheni-
col, ampicillin, and trimethoprim, 54 
(96%) were also resistant to cipro-
ﬂ  oxacin at 0.125 mg/L. When tested 
for resistance to ceftriaxone and cefo-
taxime, none of the isolates (either S. 
Typhi or S. Paratyphi A) were resistant 
at 1.0 mg/L. 
Although the levels of resistance 
to ciproﬂ   oxacin were for the most 
part below that regarded as therapeu-
tic (MIC 0.25–1.0 mg/L), at least 21 
treatment failures have been docu-
mented since 2005. These ﬁ  ndings 
demonstrate that the efﬁ  cacy of cip-
roﬂ  oxacin  for  ﬁ   rst-line treatment of 
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enteric fever in the United Kingdom 
has been seriously jeopardized. In 
cases of treatment failures, commonly 
used alternative antimicrobial agents 
have included third-generation ce-
phalosporins such as ceftriaxone. The 
macrolide antimicrobial azithromycin 
is also being increasingly used, par-
ticularly for patients with hypersen-
sitivity to penicillins (5). With this in 
mind, 50 S. Typhi and 40 S. Paratyphi 
A strains isolated from January 2005 
through December 2006, which ex-
hibited resistance to ciproﬂ  oxacin at 
0.125 mg/L, were tested for resistance 
to azithromycin by Etest. Results in-
dicated that none of the isolates of S. 
Typhi exhibited MICs >8 mg/L, which 
corresponded to the MIC to azithromy-
cin of a drug-sensitive control strain 
of S. Typhi (range 4–8 mg/L, MIC90 
6 mg/L). For S. Paratyphi A, none 
of the isolates exhibited MICs >12 
mg/L, corresponding to that of a drug-
sensitive control strain of this serovar 
(range 6–12 mg/L, MIC90 10 mg/L). 
Although there are no deﬁ  nitive data 
on resistance levels for azithromycin 
in relation to treatment of typhoid and 
paratyphoid, these ﬁ  ndings  suggest 
that resistance to this antimicrobial 
agent in terms of treatment efﬁ  cacy 
has not yet been jeopardized. 
These results indicate that the 
availability of effective antimicrobial 
agents for the treatment of typhoid 
and paratyphoid infection is becom-
ing increasingly limited for patients 
in the United Kingdom. Nevertheless, 
despite the dramatic upsurge in the oc-
currence of strains with decreased sus-
ceptibility, ciproﬂ  oxacin still remains 
the drug of choice for many physi-
cians. It is reassuring that in cases of 
treatment failure, third-generation ce-
phalosporins such as ceftriaxone and 
macrolide antimicrobial agents such 
as azithromycin appear to be viable 
alternatives. 
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Usutu Virus 
Sequences in 
Culex pipiens 
(Diptera: Culicidae), 
Spain
To the Editor:  Usutu  virus 
(USUV) is an arbovirus and a member 
of the mosquito-borne cluster within 
the Flavivirus genus. USUV belongs 
to the Japanese encephalitis virus an-
tigenic group, which is closely related 
to pathogens such as West Nile virus 
(WNV) (1).
USUV has been isolated from a 
human in the Central African Repub-
lic and from several mosquito species 
from tropical and subtropical Africa 
(2). In late summer 2001, USUV 
emerged in central Europe and caused 
deaths in several species of resident 
birds in Austria (3). However, moni-
toring of USUV in dead birds from 
2003 through 2005 showed that the 
absolute numbers of USUV–associ-
ated bird deaths declined, although 
USUV detection persisted in bird tis-
sues (4). This decrease in USUV-as-
sociated bird deaths was attributed to 
herd immunity in the bird population 
(5). In the summer of 2005, USUV 
was detected in a blackbird in Hunga-
ry. The complete genomic sequence 
of the Hungarian USUV strain shared 
99.9% identity with the strain circu-
lating in Austria since 2001 (6). On 
the other hand, neutralizing antibod-
ies against USUV have been detected 
in sera of resident and migrant birds 
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Table. Incidence of resistance/decreased susceptibility to key antimicrobial agents in isolates of Salmonella enterica serovars Typhi 
and Paratyphi A, United Kingdom, 2001–2006* 
% S. Typhi resistant to  % S. Paratyphi A resistant to 
Year No.  studied  CA T m C p L CpH No. studied  CA T m C p L CpH
2001 170 24 23 23 35 0 232 28 27 27 23 2
2002 150 18 17 17 35 1 149 10 9 10 39 3
2003 218 20 20 21 43 1 177 17 18 17 65 12
2004 215 23 23 24 47 2 221 5 5 5 70 14
2005 222 29 29 29 62 2 217 7 7 7 60 12
2006 240 23 24 24 68 2 278 2 3 2 64 9
*C, chloramphenicol; A, ampicillin, Tm, trimethoprim, CpL,ciprofloxacin MIC 0.25–1.0 mg/L; CpH, ciprofloxacin MIC >1.0 mg/L. No isolates exhibited 
resistance to ceftriaxone or cefotaxime; of 50 S. Typhi and 40 S. Paratyphi A isolated in 2005 and 2006, the MIC to azithromycin by E test (AB Biodisk, 
Solna, Sweden) was not greater than 8 mg/L for S. Typhi and 12 mg/L for S. Paratyphi A, which corresponds to those of drug-sensitive controls of the 
respective serotypes. 